Open AccessComparative study of the efficacy of different regimens of intermittent subcutaneous dosing of erythropoietin β in treatment of renal anemia in chronic dialysis patients
Author(s) -
Vladimir Nešić,
Vladimir Oštrić,
Zoran Kovačević,
Nada Dimković,
S Curić,
Marina Lazarević,
Marina Ratković,
Jasmina Bogdanović,
Rosa Jelačić
Publication year - 2005
Publication title -
medicinski pregled
Language(s) - English
Resource type - Journals
eISSN - 1820-7383
pISSN - 0025-8105
DOI - 10.2298/mpns0506279n
Subject(s) - medicine , erythropoietin , anemia , regimen , hematocrit , hemodialysis , dosing , hemoglobin , dialysis , transferrin saturation , clinical trial , surgery , gastroenterology , iron deficiency
The use of erythropoietin (EPO) in the treatment of renal anemia is justified by more than 15 years of experience. Clinical trials have shown that subcutaneous erythropoietin beta (Recormon - F. Hoffmann-La Roche) therapy once weekly, or even once every two weeks has proven successful. The aim of this study was to evaluate the efficacy of different regimes of Recormon therapy in maintaining stable levels of hemoglobin (Hb) and hematocrit (HCT) in hemodialysis patients.